The pharmacological or genetic inhibition of STAT3 was effective for the treatment of skeletal muscle atrophy induced by chronic kidney disease (Zhang et al., 2013), cancer (Silva et al., 2015), and immobilization (Huang, et al., 2020). The gene discussed is STAT3; the disease is chronic kidney disease.